RxDoctor Payments DataLook up a doctor →

Andrew Nik, MD

Vascular Neurology · Colton, CANPI 1316177520

Payments from drug & device makers

$13,761in general payments, 2019–2025

Across 734 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Biogen$925
  • Acadia Pharmaceuticals Inc$907
  • Supernus Pharmaceuticals, Inc.$823
  • AstraZeneca$583
  • UCB, Inc.$563
  • plus $6K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)259$3,911
Biogen55$925
Acadia Pharmaceuticals Inc35$907
Supernus Pharmaceuticals, Inc.49$823
AstraZeneca(2 entities)21$583
UCB, Inc.27$563
SK Life Science, Inc.24$559
Pfizer28$465
Teva Pharmaceuticals USA, Inc.20$404
Biohaven Pharmaceuticals, Inc.20$358
Sunovion Pharmaceuticals Inc.18$329
MDD US Operations, LLC12$314
Lundbeck LLC15$305
Novartis10$225
Amgen(2 entities)8$219
Lilly USA, LLC12$209
Argenx US, Inc.7$173
Avion Pharmaceuticals7$159
Abbott6$133
Corium, LLC5$128
Eisai Inc.6$127
Biohaven Pharmaceutical Holding Company Ltd.7$125
Amneal Pharmaceuticals LLC5$114
Adamas Pharmaceuticals, Inc.5$105
Sanofi5$105
Boston Scientific5$96
Genentech USA, Inc.4$94
Livanova USA, Inc.4$89
Neurelis, Inc.3$86
Harmony Biosciences LLC3$74
Aquestive Therapeutics, Inc.4$68
Greenwich Biosciences, Inc.2$68
Zyla Life Sciences, Inc.4$62
Neurocrine Biosciences, Inc.3$59
Portola Pharmaceuticals, LLC2$57
Kyowa Kirin, Inc.2$48
Upsher-smith Laboratories LLC2$48
Octapharma USA, Inc.2$47
Averitas Pharma Inc.2$45
Acorda Therapeutics, Inc2$42
Otsuka America Pharmaceutical, Inc.2$38
GE HealthCare1$37
Banner Life Sciences, LLC2$35
Jazz Pharmaceuticals Inc.1$35
Johnson & Johnson(2 entities)2$33
Assertio Therapeutics, Inc.2$33
Axsome Therapeutics, Inc.1$29
Merz Pharmaceuticals, LLC1$27
Cycle Pharmaceuticals Inc1$26
Alnylam Pharmaceuticals Inc.1$24
Noctrix Health, Inc.1$24
Tanabe Pharma America, Inc.1$24
Avanir Pharmaceuticals, Inc.1$23
TG Therapeutics, Inc.1$22
Neuropace, Inc.1$19
Aucta Pharmaceuticals, Inc.1$18
Takeda Pharmaceuticals U.S.A., Inc.1$17
Arbor Pharmaceuticals, Inc.1$16
GRT US Holding, Inc.1$14
CSL Behring1$12

How this compares

$13,761 in reported general payments places this provider in the 60th percentile of 58 vascular neurology providers in California.

See all vascular neurology providers in California

Medicare billing

Part B allowed, 2024
$199,023
Medicare patients
602
Services billed
4,777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other vascular neurology in Colton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →